Litcius/Paper detail

Validation of Ultrasound and Computed Tomography-Based Risk Stratification System and Biopsy Criteria for Cervical Lymph Nodes in Preoperative Patients With Thyroid Cancer

Young Hun Jeon, Ji Ye Lee, Roh‐Eul Yoo, Jung Hyo Rhim, Kyung Hoon Lee, Kyu Sung Choi, Inpyeong Hwang, Koung Mi Kang, Ji‐hoon Kim

2023Korean Journal of Radiology16 citationsDOIOpen Access PDF

Abstract

OBJECTIVE: This study aimed to validate the risk stratification system (RSS) and biopsy criteria for cervical lymph nodes (LNs) proposed by the Korean Society of Thyroid Radiology (KSThR). MATERIALS AND METHODS: This retrospective study included a consecutive series of preoperative patients with thyroid cancer who underwent LN biopsy, ultrasound (US), and computed tomography (CT) between December 2006 and June 2015. LNs were categorized as probably benign, indeterminate, or suspicious according to the current US- and CT-based RSS and the size thresholds for cervical LN biopsy as suggested by the KSThR. The diagnostic performance and unnecessary biopsy rates were calculated. RESULTS: ≥ 0.177). The criteria covering only suspicious LNs showed higher specificity and lower unnecessary biopsy rates than the current criteria, while maintaining sensitivity in all imaging modalities. CONCLUSION: Integrative evaluation of US and CT helps in reducing the proportion of indeterminate LNs and the malignancy risk among them. Nodal size did not affect the malignancy risk of LNs, and the addition of indeterminate LNs to biopsy candidates did not have an advantage in detecting LN metastases in all imaging modalities.

Topics & Concepts

MedicineMalignancyIndeterminateRadiologyBiopsyUltrasoundThyroid cancerRetrospective cohort studyRisk stratificationThyroidSurgeryInternal medicinePure mathematicsMathematicsThyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid SurgeryHead and Neck Cancer Studies
Validation of Ultrasound and Computed Tomography-Based Risk Stratification System and Biopsy Criteria for Cervical Lymph Nodes in Preoperative Patients With Thyroid Cancer | Litcius